In 13,165 patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior to dulaglutide for cardiovascular death, MI or stroke (12.2% vs 13.1%; HR 0.92, 95.3% CI 0.83-1.01) but not superior; more GI adverse events.
Clinical trialn = 13,299
Nicholls et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes